ADA: Novo Nordisk's Big Hopes For Victoza Follow-On's Weight Loss Benefits
Executive Summary
Novo Nordisk AS's semaglutide has the potential to rule the GLP-1 space for treatment of type 2 diabetes because of its strong efficacy and greater effects on weight loss, Chief Medical Officer Alan Moses said during the 2016 American Diabetes Association annual conference, where the company reported updates from the ongoing Phase III SUSTAIN clinical trial program.